Journal of the American College of Cardiology

publication venue for

RISK STRATIFICATION FOR AMPUTATION IN PATIENTS WITH SYMPTOMATIC PAD AFTER LOWER EXTREMITY REVASCULARIZATION: INSIGHTS FROM VOYAGER PAD 2024
Early Risk of Major Adverse Limb Events Following Lower Extremity Revascularization in the VOYAGER-PAD Trial 2023
Impact of Artificial Intelligence-Enhanced OCT Software on Percutaneous Coronary Intervention Decisions 2023
DESIGN AND INITIAL RESULTS OF AN ANGIOGRAPHIC CORE LAB FROM THE VOYAGER PAD TRIAL 2023
ABC-AF STROKE AND BLEEDING SCORES ARE USEFUL TOOLS TO ESTIMATE THE BALANCE BETWEEN BENEFITS AND RISKS WITH DIFFERENT ANTITHROMBOTIC TREATMENTS IN PATIENTS WITH ATRIAL FIBRILLATION: INSIGHTS FROM THE ARISTOTLE AND RE-LY TRIALS 2022
A Computed Tomography Protocol to Evaluate Coronary Artery Disease Prior to Transcatheter Aortic Valve Replacement 2021
Intra-Aortic Pump Provides Acute Hemodynamic Benefit in Preclinical Model of STEMI 2021
Intra-Aortic Unloading Before Reperfusion Reduces Infarct Size in a Preclinical Model of STEMI 2021
MITRAL VALVE REPAIR WITH LEAFLET PRESERVATION VS. LEAFLET RESECTION AND VENTRICULAR REMODELING - A SUB-ANALYSIS OF THE RANDOMIZED CAMRA STUDY - 2021
CLINICAL PHENOGROUPS ARE MORE EFFECTIVE THAN LEFT VENTRICULAR EJECTION FRACTION CATEGORIES IN STRATIFYING HEART FAILURE OUTCOMES 2021
CLINICAL TRIAL CHARACTERISTICS ASSOCIATED WITH THE INCLUSION OF WOMEN IN HEART FAILURE TRIAL STEERING COMMITTEES: A SYSTEMATIC REVIEW 2021
MAJOR CARDIOVASCULAR EVENTS FOLLOWING ENDOVASCULAR ANEURYSM REPAIR 2021
MORBIDITY AND MORTALITY IN PULMONARY HYPERTENSION AFTER NON-CARDIAC SURGERY: A SYSTEMATIC REVIEW AND META-ANALYSIS 2021
REMOTE ECG MONITORING TO REDUCE COMPLICATIONS FOLLOWING TRANSCATHETER AORTIC VALVE IMPLANTATIONS - THE REDIRECT TAVI STUDY 2021
THE ASSOCIATION BETWEEN SEX, RACE, SOCIOECONOMIC STATUS, AND IN-HOSPITAL ALL-CAUSE MORTALITY AMONG PATIENTS ADMITTED FOR HEART FAILURE: A RETROSPECTIVE COHORT STUDY 2021
PATIENT SELECTION, REGION AND TREATING PHYSICIAN ARE RELATED TO ESTIMATES OF ORAL ANTICOAGULATION USE IN ATRIAL FIBRILLATION: A SYSTEMATIC REVIEW AND META-ANALYSIS 2020
ASSOCIATION BETWEEN HIGH-SENSITIVITY TROPONIN I AND MAJOR CARDIOVASCULAR EVENTS AFTER NON-CARDIAC SURGERY 2020
DULAGLUTIDE REDUCES HBA1C IRRESPECTIVE OF ANTIHYPERGLYCEMIC AGENTS, DURATION OF DIABETES, BMI AND WEIGHT LOSS: A POST HOC ANALYSIS FROM THE REWIND TRIAL 2020
FACTORS ASSOCIATED WITH UNDER-ENROLMENT OF FEMALES IN CLINICAL TRIALS OF HEART FAILURE WITH REDUCED EJECTION FRACTION: A SYSTEMATIC REVIEW AND META-ANALYSIS 2020
PREGNANCY IN WOMEN WITH HEART DISEASE: IMPACT OF OBESITY ON MATERNAL AND FETAL OUTCOMES 2020
SINGLE ORAL DOSE ANTI-ARRHYTHMIC DRUGS FOR CARDIOVERSION OF RECENT-ONSET ATRIAL FIBRILLATION EPISODES: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS 2020
THE EFFECT OF EXERCISE ON ALL-CAUSE MORTALITY IN PATIENTS WITH SUBCLINICAL ATHEROSCLEROSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS 2020
TCT-236 Coronary Artery Bypass Grafting in Patients Presenting With ST-Segment Elevation Myocardial Infarction: The Optimal Timing and Impact on Outcomes: Insights From the TOTAL Trial 2019
TCT-487 Heart Failure in ST-Segment Elevation Myocardial Infarction, Predictors and Prognostic Impact: Insights From the TOTAL Trial 2019
CARDIOVASCULAR EVENTS IN PATIENTS RECEIVING SULODEXIDE VERSUS CONTROL: SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS 2019
COMPARISON OF JNJ9375, A THROMBIN EXOSITE 1-DIRECTED ANTIBODY, WITH APIXABAN FOR THROMBOPROPHYLAXIS AFTER ELECTIVE KNEE REPLACEMENT SURGERY: TEXT-TKR STUDY 2019
DYSGLYCEMIA, EJECTION FRACTION, AND THE RISK OF HEART FAILURE OR CARDIOVASCULAR DEATH IN PATIENTS WITH TYPE 2 DIABETES AND A RECENT ACUTE CORONARY SYNDROME 2019
FEASIBILITY AND EFFECT OF REMOTE AMBULATORY HEART RHYTHM MONITORING PRE AND POST TAVI 2019
INTERVENTIONAL CARDIOLOGIST POINT OF CARE TREATMENT DECISION VERSUS VIRTUAL HEART TEAM RETROSPECTIVE EVALUATION OF MULTIVESSEL CORONARY ARTERY DISEASE: DIFFERENCES OF OPINION 2019
LONG-TERM TREATMENT WITH APIXABAN OF PARTICIPANTS FOLLOWING CONCLUSION OF AVERROES 2019
TESTOSTERONE AND SEX HORMONE-BINDING GLOBULIN IN DYSGLYCEMIC WOMEN AT HIGH CARDIOVASCULAR RISK: A REPORT FROM THE OUTCOME REDUCTION WITH AN INITIAL GLARGINE INTERVENTION TRIAL 2019
TCT-223 Efficacy and Safety of Transfemoral Transcatheter Aortic Valve Replacement under General Anesthesia versus Local Anesthesia. Insights from TRYTOM Registry (International, Multicenter, Latin-American Registry) 2018
TCT-299 Pulse Wave Velocity and Aortic Distensibility in Patients with Hypertensive Response Post Transcatheter Aortic Valve Replacement 2018
CARDIOVASCULAR SIGNALING PROTEINS AS PREDICTORS OF DOXORUBICIN-RELATED CARDIAC EFFECTS IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA 2018
CHARACTERIZATION OF 6,122 PATIENTS WITH ACUTE VENOUS THROMBOEMBOLISM IN ROUTINE CLINICAL PRACTICE: RE-COVERY DVT/PETM PROSPECTIVE GLOBAL COHORT STUDY 2018
CLINICAL IMPACT OF DIRECT STENTING AND INTERACTION WITH THROMBUS ASPIRATION IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: THROMBECTOMY TRIALISTS COLLABORATION 2018
COMPARISON OF RATES OF BLEEDING AND VASCULAR COMPLICATIONS BEFORE, DURING, AND AFTER TRIAL ENROLLMENT IN THE SAFE-PCI TRIAL FOR WOMEN 2018
RENAL IMPAIRMENT DOES NOT COMPROMISE DABIGATRAN REVERSAL BY IDARUCIZUMAB 2018
THE ROLE OF VENTRICULAR STROKE WORK AND VASCULAR IMPEDANCE IN DEFINING AORTIC STENOSIS 2018
TRADITIONAL CARDIOVASCULAR RISK FACTORS AND THE RISK OF AORTIC VALVE DISEASE: A SYSTEMATIC REVIEW 2018
Clinical results at a very long-term follow-up of percutaneous coronary intervention in bifurcated left main coronary artery 2017
High Syntax score and left main percutaneous coronary intervention in high risk patients. Results at 10-year follow-up 2017
Ten years follow-up results of left main percutaneous coronary intervention in elderly patients 2017
TCT-796 Percutaneous coronary intervention in left main coronary artery disease concomitant with acute coronary syndrome. Clinical results at a long-term follow-up 2017
TCT-797 Ten years follow-up results of primary percutaneous coronary intervention in left main coronary artery disease 2017
TCT-814 Results of left main percutaneous coronary intervention in diabetic patients at a long-term follow-up 2017
TCT-831 Results of left main percutaneous coronary intervention with zotarolimus eluting stent at a very long-term follow-up 2017
AN UNSUSPECTED CASE OF MYOCARDITIS ASSOCIATED WITH NIVOLUMAB USE 2017
ASSESSMENT OF THE SAFETY OF PERFORMING CORONARY ANGIOPLASTY WITHOUT INTERRUPTING ORAL ANTICOAGULANTS 2017
IMPACT OF PREPROCEDURAL THROMBOCYTOPENIA ON SAFETY OF PERFORMING PERCUTANEOUS CORONARY INTERVENTION IN CANCER PATIENTS 2017
INCIDENCE AND PREDICTORS OF NO REFLOW PHENOMENON: INSIGHTS FROM THE TOTAL TRIAL 2017
MINERALOCORTICOID RECEPTOR ANTAGONISTS IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED TRIALS 2017
ONE-YEAR OUTCOME OF ACUTE STENT THROMBOSIS: INSIGHTS FROM THE TOTAL TRIAL 2017
PERSISTENCE WITH THERAPY IN PATIENTS WITH ATRIAL FIBRILLATION: THE GLORIA-AF REGISTRY 2017
PREDICTORS OF ANTICOAGULANT PRESCRIPTION IN PATIENTS WITH ATRIAL FIBRILLATION IN NORTH AMERICA: THE GLORIA-AF REGISTRY 2017
THE PRESCRIBING OF ANTIPLATELET THERAPY ONLY IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION: RESULTS FROM THE GARFIELD-AF REGISTRY 2017
UTILITY OF UNFRACTIONATED HEPARIN IN TRANSRADIAL CARDIAC CATHETERIZATION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED STUDIES 2017
TCT-285 Ten year follow-up results of left main percutaneous coronary intervention in elderly patients 2016
TCT-293 High Syntax score and left main percutaneous coronary intervention in high risk patients. Results at a 10 year follow-up 2016
TCT-350 Clinical Results At A Long-Term Follow-Up Of Percutaneous Coronary Intervention In Left Main Coronary Artery Disease 2016
ASSOCIATION BETWEEN BLOOD PRESSURE VARIABILITY AND LONG TERM SURVIVAL IN PATIENTS WITH STABLE ISCHEMIC HEART DISEASE: A POST-HOC ANALYSIS OF THE COURAGE TRIAL 2016
CHA2DS2-VASC VERSUS HAS-BLED SCORE FOR PREDICTING RISK OF MAJOR BLEEDING AND ISCHEMIC STROKE IN ATRIAL FIBRILLATION: INSIGHTS FROM RE-LY TRIAL 2016
CLINICAL OUTCOMES OF ATRIAL FIBRILLATION PATIENTS RECEIVING DIGOXIN IN THE RE-LY ® TRIAL 2016
EFFECT OF PERCUTANEOUS REVASCULARIZATION ADDED TO OPTIMAL MEDICAL THERAPY ON CLINICAL OUTCOMES IN PATIENTS WITH PRIOR MYOCARDIAL INFARCTION, HEART FAILURE, OR REDUCED SYSTOLIC FUNCTION: A POST HOC ANALYSIS OF THE COURAGE TRIAL 2016
EFFECTS OF DABIGATRAN VERSUS WARFARIN IN RELATION TO LEFT VENTRICULAR HYPERTROPHY IN ATRIAL FIBRILLATION 2016
EXTERNAL VALIDATION OF THE BIOMARKER-BASED ABC-BLEEDING RISK SCORE FOR ATRIAL FIBRILLATION 2016
EXTERNAL VALIDATION OF THE BIOMARKER-BASED ABC-STROKE RISK SCORE FOR ATRIAL FIBRILLATION 2016
HEALTH CARE RESOURCE UTILIZATION IN PATIENTS REQUIRING URGENT SURGICAL/INTERVENTIONAL MANAGEMENT WHILE TAKING DABIGATRAN: INTERIM RESULTS FROM THE RE-VERSE AD STUDY 2016
IDARUCIZUMAB FOR REVERSAL OF THE ANTICOAGULANT EFFECTS OF DABIGATRAN IN PATIENTS IN AN EMERGENCY SETTING OF MAJOR BLEEDING, URGENT SURGERY, OR INTERVENTIONS 2016
PATIENT SELF-ASSESSED HOME BP READINGS ARE AN INACCURATE SURROGATE FOR 24-HOUR AMBULATORY BP MONITORING 2016
QUANTIFICATION AND SYSTEMATIC DIFFERENTIATION OF IMPACT OF PARAVALVULAR LEAKAGE FOLLOWING TRANSCATHETER AORTIC VALVE REPLACEMENT 2016
RECURRENT VENOUS THROMBOEMBOLISM IN PULMONARY EMBOLISM PATIENTS WITH RIGHT VENTRICULAR DYSFUNCTION IN THE HOKUSAI-VTE STUDY 2016
SUCCESSFUL VALVE-IN-VALVE TAVI IN PREGNANCY FOR SEVERE DEGENERATIVE BIOPROSTHETIC AORTIC VALVE STENOSIS 2016
THE PROGNOSTIC SIGNIFICANCE OF ST RESOLUTION AND TEMPORAL ECG FEATURES IN PRIMARY PCI PATIENTS: A SUBSTUDY OF THE TOTAL TRIAL 2016
TCT-285 Radiation dose reduction in the cardiac catheterization laboratory utilising a novel protocol 2015
TCT-316 Characteristics Of Culprit Lesions Vs. Non-Culprit Lesions In Patients With ST-Elevation Myocardial Infarction – An Optical Coherence Tomography Study. On Behalf Of The TOTAL-OCT Investigators 2015
TCT-339 Different Pattern of Neoatherosclerosis for DES versus BMS in Very Late Stent Thrombosis 2015
TCT-410 Results Of Percutaneous Coronary Intervention Of “De Novo” Lesions With Sequent Please® Paclitaxel Eluting Balloon Catheter At A Very Long-Term Follow-Up 2015
TCT-411 Results Of Percutaneous Coronary Intervention With Sequent Please® Paclitaxel Eluting Balloon Catheter In Diabetic Patients At A Very Long-Term Follow-Up 2015
TCT-46 OCT-based management of late stent thrombosis: results from the SAFE registry 2015
TCT-49 Underlying stenosis severity is independent of culprit plaque morphology in STEMI – an optical coherence tomography study 2015
ASSESSING THE IMPACT OF MEDICATION ADHERENCE ON LONG-TERM OUTCOMES IN PATIENTS WITH DIABETES 2015
CARDIAC CATHETERIZATION IN CANCER PATIENTS WITH THROMBOCYTOPENIA: 4-YEAR EXPERIENCE FROM A HIGH VOLUME CANCER CENTER CARDIAC CATHETERIZATION LABORATORY 2015
ENDOCARDITIS IN CANCER PATIENTS WITH AND WITHOUT THROMBOCYTOPENIA: PREVALENCE AND COMPLICATION RATES 2015
FATAL BLEEDING, CASE-FATALITY RATE OF MAJOR BLEEDING AND ALL-CAUSE MORTALITY IN PATIENTS TAKING TARGET-SPECIFIC ORAL ANTICOAGULANT, A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS 2015
PATIENT AND SYSTEM-RELATED GAPS IN EMERGENCY MEDICAL SERVICES USE IN ST-ELEVATION MYOCARDIAL INFARCTION: RESULTS FROM THE THIRD GULF REGISTRY OF ACUTE CORONARY EVENTS 2015
PERIOPERATIVE ADVERSE OUTCOMES IN PATIENTS WITH ATRIAL FIBRILLATION TAKING EDOXABAN OR WARFARIN: ANALYSIS OF THE ENGAGE AF-TIMI 48 TRIAL 2015
TAKOTSUBO CARDIOMYOPATHY IN CANCER PATIENTS: TRIGGERS, RECOVERY, AND RESUMPTION OF THERAPY 2015
TCT- 145 RADIATION PROTECT: A randomized trial to assess the effectiveness of a novel pelvic lead shield and a novel, non-lead surgical cap to reduce operator radiation exposure during coronary angiography or intervention 2014
TCT-135 A Systematic Review and Meta-analysis of Randomized trials of Manual Thrombectomy in ST Elevation Myocardial Infarction 2014
TCT-147 Patient radiation exposure with a novel X-ray imaging technology during coronary angiography and angioplasty 2014
TCT-504 Bleeding risk in Acute Coronary Syndrome submitted to PCI with new oral antiplatelet agents 2014
BASELINE EXERCISE CAPACITY AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH STABLE ISCHEMIC HEART DISEASE: A POST HOC ANALYSIS OF THE COURAGE TRIAL 2014
BASELINE EXERCISE CAPACITY AND IMPROVEMENT IN QUALITY OF LIFE IN PATIENTS WITH STABLE ISCHEMIC HEART DISEASE: A POST HOC ANALYSIS OF THE COURAGE TRIAL 2014
COMPARISON OF DABIGATRAN VERSUS WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION AND VALVULAR HEART DISEASE: THE RE-LY® TRIAL 2014
EFFECT OF ROSUVASTATIN THERAPY ON ARTERIAL WALL CHANGES IN CHILDREN AND ADOLESCENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA: RESULTS FROM THE CHARON STUDY 2014
EFFICACY AND SAFETY OF ROSUVASTATIN THERAPY FOR CHILDREN AND ADOLESCENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA: RESULTS FROM THE CHARON STUDY 2014
PARAVALVULAR LEAK OF TRANSCATHETER AORTIC VALVES: QUANTITATIVE ANALYSIS USING CARDIAC MR 2014
RADIATION DOSIMETRY AND RADIATION BEST PRACTICE USE FOR NUCLEAR CARDIOLOGY IN THE UNITED STATES: RESULTS FROM THE 66 COUNTRY INCAPS (IAEA NUCLEAR CARDIOLOGY PROTOCOLS) STUDY 2014
RESTING HEART RATE AND CHANGES IN HEART RATE ARE ASSOCIATED WITH ADVERSE OUTCOME IN HEART FAILURE PATIENTS WITHOUT ATRIAL FIBRILLATION: AN ANALYSIS OF THE CHARM PROGRAM 2014
SAFETY AND EFFICACY OF TRANSRADIAL APPROACH FOR CORONARY ANGIOGRAPHY AND INTERVENTION IN THE ELDERLY: A SYSTEMIC REVIEW AND META-ANALYSIS 2014
THE GLOBAL REGISTRY PROGRAM ON LONG-TERM ORAL ANTI-THROMBOTIC TREATMENT IN PATIENTS WITH ATRIAL FIBRILLATION (GLORIA-AF): FIRST ASSESSMENT OF BASELINE CHARACTERISTICS OF DABIGATRAN AND VKA COHORTS IN NORTH AMERICA 2014
THE STELLA SCORE: A NOVEL COMPUTED TOMOGRAPHY ANGIOGRAPHIC INDEX TO PREDICT FUNCTIONALLY SIGNIFICANT CORONARY STENOSES IN LESIONS WITH INTERMEDIATE STENOSIS SEVERITY 2014
VARIATION IN RADIATION DOSES FROM NUCLEAR CARDIOLOGY PROCEDURES: RESULTS FROM THE 66 COUNTRY INCAPS (IAEA NUCLEAR CARDIOLOGY PROTOCOLS) STUDY 2014
TCT-733 Coronary Flow Reserve Pre and Post Transcatheter Aortic Valve Implantation in Severe Aortic Stenosis: An Invasive Evaluation Study of Coronary Flow Dynamics. 2013
ASSOCIATION BETWEEN GLOBAL LEFT VENTRICULAR LONGITUDINAL STRAIN AND LEFT VENTRICULAR REMODELING AFTER STEMI 2013
EFFECT OF DABIGATRAN ON SERUM APOLIPOPROTEIN B AND APOLIPOPROTEIN A1 CONCENTRATIONS 2013
IMPACT OF WEIGHT REDUCTION ON PERICARDIAL FAT AND CARDIAC STRUCTURE IN PATIENTS WITH ATRIAL FIBRILLATION 2013
LIMITATIONS OF AVAILABLE METHODS FOR CT ANGIOGRAPHIC ANALYSIS FOR DETECTION OF IN-STENT RESTENOSIS AFTER LEFT MAIN CORONARY STENTING 2013
MORBIDITY AND MORTALITY IN DIABETICS WITH HEART FAILURE AND A PRESERVED EJECTION FRACTION: RESULTS FROM THE I-PRESERVE TRIAL 2013
PHYSICAL ACTIVITY AND ITS RELATIONSHIP WITH OBESITY HYPERTENSION AND DIABETES IN URBAN AND RURAL CHINA: THE PURE CHINA STUDY 2013
PREVALENCE AND CLINICAL SIGNIFICANCE OF RECURRENT AND UNREMITTING ANGINA WITH PERCUTANEOUS INTERVENTION VERSUS OPTIMAL MEDICAL THERAPY IN PATIENTS WITH STABLE ISCHEMIC HEART DISEASE: A POST HOC ANALYSIS OF THE CLINICAL OUTCOMES UTILIZING REVASCULARIZATION AND AGGRESSIVE DRUG EVALUATION TRIAL 2013
PREVALENCE AND RISK FACTORS OF LEFT VENTRICULAR THROMBUS IN NONISCHEMIC CARDIOMYOPATHY PATIENTS WITH SEVERE LEFT VENTRICULAR SYSTOLIC DYSFUNCTION 2013
THE DIAGNOSTIC ACCURACY OF 64-SLICE CT ANGIOGRAPHY USING CONTRAST DENSITY GRADIENT ANALYSIS FOR THE DETECTION OF IN-STENT RESTENOSIS AFTER LEFT MAIN CORONARY STENTING 2013
URBAN AND RURAL DIFFERENCES OF BLOOD PRESSURE AND HYPERTENSION CONTROL IN CHINESE COMMUNITIES: PURE CHINA STUDY 2013
TCT-235 Accuracy of 320 computed tomography coronary angiography in detection of functionally significant stenoses - comparison with FFR 2012
TCT-415 Transradial Catheterization is Not Associated With Increased Patient Radiation Exposure Compared to Transfemoral Access: A Meta-analysis 2012
TCT-487 Door-to-Balloon Time as a Function of Mode of Referral: Results from the Ontario Provincial Cardiac Care Network Database 2012
TCT-604 Per-Lesion Inter-Observer Variability and Impact on Syntax Score 2012
INDUCTION OF LV DYSSYNCHRONY BY RIGHT VENTRICULAR APICAL PACING IS ASSOCIATED WITH INCREASED ALL-CAUSE MORTALITY AND HEART FAILURE HOSPITALIZATIONS AT LONG-TERM FOLLOW-UP 2012
A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS OF CONVENTIONAL STENTING VERSUS DIRECT STENTING IN PATIENTS WITH AN ACUTE MYOCARDIAL INFARCTION 2012
BLEEDING WITH ASPIRIN AND APIXABAN IN PATIENTS UNSUITABLE FOR VITAMIN K ANTAGONIST THERAPY: THE AVERROES STUDY 2012
DEPRESSION AND NEUROHORMONAL MODULATION IN PATIENTS UNDERGOING TREATMENT FOR CONGESTIVE HEART FAILURE: RANDOMIZED EVALUATION OF STRATEGIES FOR LEFT VENTRICULAR DYSFUNCTION SUBSTUDY 2012
IMPACT OF CHRONIC THROMBOCYTOPENIA IN PATIENTS WITH CORONARY ARTERY DISEASE AND CANCER 2012
LONG-TERM OUTCOMES FOLLOWING TRANSCATHETER AORTIC VALVE IMPLANTATION: INSIGHTS ON PROGNOSTIC FACTORS AND VALVE DURABILITY FROM THE CANADIAN MULTICENTER EXPERIENCE 2012
RELIABILITY OF BRUISE MEASUREMENT FOLLOWING INVASIVE CARDIAC PROCEDURES 2012
THE CHA2DS2-VASC SCORE IDENTIFIES AF PATIENTS WITH A CHADS2 SCORE OF 0 OR 1 TREATED WITH ANTIPLATELET THERAPY WHO ARE UNLIKELY TO BENEFIT FROM ORAL ANTICOAGULANT THERAPY 2012
VENOUS THROMBOEMBOLISM IN PATIENTS WITH DIABETES MELLITUS 2012
ACUTE PERIPHERAL ARTERIAL ISCHEMIC EVENTS IN CANCER PATIENTS 2011
COMPARISON OF TRANSRADIAL AND FEMORAL APPROACHES FOR PERCUTANEOUS CORONARY INTERVENTIONS: A HIERARCHICAL BAYESIAN META-ANALYSIS 2011
DABIGATRAN ETEXILATE VERSUS WARFARIN IN PATIENTS WITH DIFFERENT TYPES OF ATRIAL FIBRILLATION: A RE-LY® SUBGROUP ANALYSIS 2011
DABIGATRAN VERSUS WARFARIN AND IMPACT OF CHAD2-VASC SCORE ON OUTCOME IN ATRIAL FIBRILLATION PATIENTS: A RE-LY SUBGROUP ANALYSIS 2011
INTERLEUKIN-6 AND C-REACTIVE PROTEIN AND RISK FOR DEATH AND CARDIOVASCULAR EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION 2011
INTRACORONARY SALBUTAMOL, SEGMENTAL PLAQUE BURDEN AND FOCAL CORONARY ENDOTHELIAL FUNCTION: NOVEL MECHANISTIC INSIGHTS FROM AN IN VIVO INTRAVASCULAR ULTRASOUND STUDY 2011
META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS COMPARING PERCUTANEOUS CORONARY INTERVENTION WITH MEDICAL THERAPY IN PATIENTS WITH STABLE ANGINA 2011
SELECTIVE PROFILING OF CARDIAC NEUROHORMONES PREDICTS MODES OF DEATH IN CONGESTIVE HEART FAILURE 2011
DABIGATRAN VERSUS WARFARIN IN ATRIAL FIBRILLATION PATIENTS WITH LOW, MODERATE AND HIGH CHADS2 SCORE: A RE-LY SUBGROUP ANALYSIS 2010
DABIGATRAN VERSUS WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION - AN ANALYSIS OF PATIENTS UNDERGOING CARDIOVERSION 2010
EFFECT OF AGE AND RENAL FUNCTION ON THE RISKS OF STROKE AND MAJOR BLEEDING WITH DABIGATRAN COMPARED TO WARFARIN: AN ANALYSIS FROM THE RE-LY STUDY 2010
INCREASING TRENDS IN HOSPITALIZATION FOR ATRIAL FIBRILLATION IN AUSTRALIA: 1998-2008 2010
INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN (IGFBP) 2: A NOVEL METABOLIC BIOMARKER STRONGLY PREDICTIVE OF FUTURE CARDIOVASCULAR EVENTS 2010
PLASMA AND TISSUE METABOLOMIC PROFILING IN A PORCINE ISCHEMIA-REPERFUSION MODEL REVEALS NOVEL EARLY MARKERS OF MYOCARDIAL INJURY 2010
Differential Clinical Outcomes Associated With Hypoglycemia and Hyperglycemia in Acute Myocardial Infarction 2009
Relationship Between NTproBNP and Exercise Capacity in Chronic Heart Failure: Baseline Data from the HF-ACTION Study 2009
Socioeconomic Status and Incident Type 2 Diabetes Mellitus: Results From the Women's Health Study 2009
Underuse of Evidence Based Methods for Management of Warfarin in Atrial Fibrillation Patients in Hamilton, Canada 2009
Alcohol intake and risk of incident atrial fibrillation in women: A prospective cohort study 2008
Clinically significant improvement in Seattle Angina Questionnaire scores in the COURAGE trial 2008
Concordance of Seattle Angina Questionnaire scores and Canadian Cardiovascular Society class of angina in the COURAGE trial 2008
Drug eluting stent among diabetics: A propensity analysis of a large population-based cohort 2008
Dyssynchrony echocardiography is inadequate in predicting clinical response to cardiac resynchronisation therapy 2008
High rates of preventable latrogenic adverse events in patients admitted to the coronary care unit 2008
Microvolt T-wave alternans and electrophysiological testing predict different arrhythmia outcomes: Lessons from the alternans before cardioverter defibrillator (ABCD) trial 2008
Predictors and outcomes of optimal medically-treated COURAGE patients who crossed over to coronary revascularization 2008
Benefits of candesartan are consistent regardless of pre-treatment systolic blood pressure in the candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) program. 2007
Black patients with symptomatic heart failure have similar outcomes and response to angiotensin receptor blockade as white patients 2007
Candesartan benefits and safety observed regardless of age. Insights from the candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) program. 2007
Comparison of the risk associated with diabetes mellitus in patients with preserved and low ejection fraction heart failure: An analysis of the candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM) program 2007
Coronary stent assessability by 64 slice multi-detector computed tomography 2007
Effects of aspirin dose on ischemic events and bleeding after percutaneous coronary intervention: Insights from the PCI-CURE study 2007
Efficacy and safety of fonclaparinux in elderly patients with ST segment elevation myocardial infarction: Data from the OASIS 6 trial 2007
Impaired therapeutic potential of bone marrow-derived endothelial progenitor cells in the metabolic syndrome and diabetes mellitus. 2007
Liver function test abnormalities and outcome in patients with chronic heart failure: Data from the candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM) program 2007
Long-term prognostic value and therapeutic implications of continuous ST-segment monitoring in acute coronary syndrome 2007
N-terminal pro BNP is associated with cardiac structure and function in elderly patients with heart failure and preserved systolic function; the iPRESERVE study 2007
Preventing contrast-induced nephropathy in high risk patients: Does the contrast agent matter? 2007
Red cell distribution width as a novel prognostic marker in heart failure: Data from the CHARM program and the duke databank 2007
Referrals in acute coronary events for cardiac catheterization, the RACE CAR study: What factors account for gender differences in cardiac catheterization referral rates? 2007
The effect of valsartan compared to valsartan/hydrochlorothiazide on plasma levels of cellular adhesion molecules: The Val-MARC trial 2007
Adverse impact of bleeding in patients with acute coronary syndromes 2006
Bleeding complications predict major cardiovascular outcomes in non ST-elevation acute coronary syndromes: Results from the OASIS-5 trial 2006
CABG and PCI rates differ between genders even with similar coronary anatomy: A computer based patient simulation explores the gender gap 2006
Candesartan improves outcome in patients with low ejection fraction heart failure, irrespective of background dose of ACE inhibitor: An analysis of the CHARM-added trial 2006
Fondaparinux is associated with substantially less major bleeding and vascular access site complications compared with enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary intervention: Insights from the OASIS 5 trial 2006
Fondaparinux versus enoxaparin in patients with acute coronary syndromes without ST-segment elevation: Impact of risk according to the GRACE score 2006
Increasing occurrence of multivessel intervention and multiple stent placement from 1999 to 2004. The Global Registry of Acute Coronary Events 2006
Left ventricular dysfunction and mortality in patients with Eisenmenger syndrome 2006
Left ventricular myocardial performance index is abnormal in patients with repaired tetralogy of Fallot 2006
Neither Ramipril nor Vitamin E reduce the incidence of atrial fibrillation. Results of the HOPE study 2006
Presence and type of provocable non pulmonary triggers for atrial fibrillation: Influence of gender and arrhythmia presentation 2006
Should warfarin be monitored by anticoagulation clinics or by physician practices? 2006
Stimulation of endothelial progenitor cells with granulocyte macrophage colony stimulating factor improves endothelial dysfunction in patients with peripheral arterial disease 2006
The efficacy and safety of fondaparinux versus enoxaparin in non-ST elevation ACS: Impact of renal dysfunction (OASIS 5) 2006
The oldest old patients have a lower chance for receiving guidelines recommended atrial fibrillation therapy. The experience of the Euro Heart Survey on atrial fibrillation 2006
Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: A meta-analysis of the randomized trials 2006
Cost comparison of four revascularization procedures in patients with multi-vessel coronary artery disease 2005
Direct bilirubin and red cell distribution width (RDW) are powerful independent predictors of outcome in chronic heart failure: Results from the CHARM program 2005
Does time of day and day of the week affect the receipt of reperfusion therapy and hospital outcomes? The global registry of acute coronary events 2005
Electrocardiographic left ventricular hypertrophy is associated with worse clinical outcomes in heart failure: Evidence from the candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM) programme 2005
Intensity of lipid lowering with statins and brachial artery vascular endothellum reactivity after acute coronary syndromes: The BRAVER trial 2005
Perioperative bridging therapy with unfractionated heparin or low-molecular-weight heparin in patients with mechanical heart valves on long-term oral, anticoagulants: Results from the REGIMEN registry 2005
Risk factors for poor outcomes in ventricular assist devices: The Pittsburgh bridge to transplant experience 2005
Short-term and long-term outcomes of off-pump and on-pump coronary artery bypass graft surgery: The Canadian off-pump CABG registry 2005
1004-48 Randomized trial of radial versus femoral access for primary and rescue angioplasty 2004
1034-212 5-Hydroxytryptamine 4 (5HT4) receptor mRNA processing in favor of the ‘b’ isoform correlates with left atrial dilatation and may predispose to atrial fibrillation after coronary artery bypass grafting 2004
1047-178 Low-density lipoprotein subfractions in a random sample of children and adolescents 2004
1049-114 Increasing atrial natriuretic peptide over time independently predicts higher short-term mortality and morbidity in heart failure 2004
1061-85 Trends in the use of effective cardiac medications in patients with acute myocardial infarction: The GRACE experience 2004
1069-113 Cause of death across full spectrum of ventricular function in patients with heart failure: The CHARM study 2004
1087-103 Plasma metalloproteinase levels are correlated with natriuretic peptide and endothelin-1 levels in patients with heart failure 2004
1098-79 Renal function predicts outcomes in acute coronary syndromes: Insights from the CURE trial 2004
1108-109 Low hemoglobin is an independent predictor of adverse fatal and nonfatal outcomes in both reduced and preserved systolic function chronic heart failure: Findings from the candesartan in heart failure assessment of reduction in mortality and morbidity program (CHARM) 2004
1124-196 Impact of elevated age and sex-adjusted body mass index in school age children on insulin resistance and lipoprotein subfractions 2004
1128-120 Importance of an oral glucose tolerance test in identifying high prevalence of dysglycemia in individuals at high cardiovascular risk 2004
1137-77 Long-term cost-effectiveness of clopidogrel in patients having percutaneous coronary intervention early after acute coronary syndrome: Results from PCI-CURE 2004
1145-122 Prevention of atrial fibrillation in symptomatic chronic heart failure by candesartan: Results from CHARM 2004
1154-85 High incidence of the metabolic syndrome in symptomatic coronary heart disease in North America during the early 21st century 2004
1160-169 Short term estrogen replacement therapy improves cardiovascular autonomic response in postmenopausal women: A double-blind randomized placebo controlled trial 2004
810-1 Impact of the angiotensin-receptor blocker candesartan in preventing diabetes in patients with heart failure 2004
827-5 Diabetic patients with acute myocardial infarction have larger infarct size, lower ejection fraction, and higher mortality 2004
834-1 Vascular and autonomic dysfunction in the asymptomatic stage of Chagas's disease 2004
835-5 Candesartan improves functional class across a broad spectrum of patients with chronic heart failure: Results of the candesartan in heart failure-assessment of reduction in mortality and morbidity programme (CHARM) 2004
Benefit of clopidogrel in patients undergoing percutaneous coronary intervention in the CURE trial receiving and not receiving an intracoronary Stent 2003
Incremental cost-effectiveness of early and long-term clopidogrel in patients undergoing percutaneous coronary infarction in the CURE trial: The PCI-CURE economic analysis 2003
Plasma norepinephrine, predicts 12-year survival in patients with reduced ejection fractions from the studies of left ventricular dysfunction (SOLVD) 2003
Plasmin-mediated proteolysis of tissue factor pathway inhibitor: Potential contributing mechanism to rethrombosis despite heparin administration following fibrinolytic therapy 2003
Randomized comparison of dalteparin versus unfractionated heparin during percutaneous coronary interventions 2003
Six-month mortality rates are lower in patients with an acute coronary syndrome treated with the combination of clopidogrel and a statin than in patients treated with either therapy alone: An analysis from the global registry of acute coronary events 2003
What is in the differential diagnosis of a B-type natriuretic peptide level of 1,000 pg/ml? 2003
Beneficial effects of ramipril on cardiovascular events in high-risk patients older than 75 years of age: Secondary outcomes from the HOPE trial 2003
International patterns in the care of acute myocardial infarction patients in the occluded artery trial (OAT): Characteristics of 1,835 screened patients 2003
Neurohumoral changes as markers of progressive left ventricular remodeling in systolic heart failure: Results of the neurohumoral substudy of the randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) 2003
Is primary angioplasty better than thrombolytic therapy in elderly patients with acute myocardial infarction? An insight from the Global Registry of Acute Coronary Events (GRACE) 2002
Prevention of post-cardiac surgery atrial fibrillation is not associated with decrease in post-operative stroke: Meta-analysis 2002
Thrombin generation after the abrupt cessation of intravenous unfractionated heparin is mediated by the extrinsic coagulation pathway 2002
Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk diabetic patients 2002
Natriuretic peptides predict left ventricular remodeling in response to metoprolol CR in patients with congestive heart failure: the RESOLVD phase II neurohumoral substudy 2002
Ramipril prevents major cardiovascular events in high-risk women: results of the HOPE trial 2002
A comparison of the impact of practice patterns on the outcomes of patients with acute coronary syndromes in the USA and Canada: Post hoc analysis of ESSENCE and TIMI 11B 2001
Ankle-brachial blood pressure index is a strong predictor for mortality and cardiovascular events: Results from the HOPE-trial 2001
Comparison of the effects of ramipril on ambulatory and office blood pressures. A HOPE substudy 2001
Detection of coronary restenosis after successfull coronary angioplasty by contrast enhanced transthoracic Doppler monitoring of coronary flow reserve 2001
Effect of gemfibrozil on brachial artery vascular reactivity in men with reduced HDL cholesterol 2001
Effects of ramipril on left ventricular mass and function in normotensive, high-risk patients with normal ejection fraction. A substudy of HOPE 2001
Factor XII activation in acute coronary syndromes: Fundamental basis for pharmacological targeting of the intrinsic coagulation cascade 2001
Impact and treatment of diabetes (Type I and II) on prognosis in acute coronary syndromes: Results from the Global Registry of Acute Coronary Events 2001
Improvement in health status at 3 months in the COURAGE trial: Seattle Angina Questionnaire results 2001
Intermediate term cardiorespiratory capacity after surgical closure of atrial septal defect in adults 2001
Myocardial reperfusion with intravenous myocardial contrast echocardiography in patients with optimal coronary recanalization (TIMI 3 flow) after acute myocardial infarction 2001
Reversibility of platelet inhibition associated with small molecule, competitive GPIIb/IIIa antagonists: An in vitro model for clinical management strategies 2001
Secular trends (1986-1997) in cholesterol assessment and management practices in patients with acute myocardial infarction: A population-based perspective 2001
Abciximab reduces early mortality but not late adverse outcomes in unselected diabetics undergoing stent implantation 2000
Abdominal adiposity as a prognostic factor for persons at high risk of cardiovascular events 2000
Cost-effectiveness of the implantable cardioverter defibrillator: Results from the Canadian Implantable Defibrillator Study (CIDS) 2000
Differences in cardiovascular disease between ethnic groups are not explained by conventional risk factors or atherosclerosis. The study of health assessment and risk in ethnic groups (SHARE) 2000
Differences in physical performance in right atrium to right ventricular conduit as compared to right atrium to pulmonary artery connectiont in adult patients with modified Fontan procedure 2000
Effects of obesity on coronary atherosclerosis, vascular remodeling and endothelial function 2000
How important is unfractionated heparin as adjunctive pharmacotherapy with GPIIb/IIIa antagonists in acute coronary syndromes? 2000
Impact of Ramipril and vitamin A on cerebrovascular events in the HOPE (Heart outcomes prevention evaluation) trial 2000
Left ventricular hypertrophy predicts death and development of heart failure in high risk patients without systolic dysfunction 2000
Prevention of heart failure by Ramipril in high risk patients without heart failure or systolic dysfunction 2000
Primary PTCA in patients with acute myocardial infarction and prior coronary artery bypass grafting 2000
Ramipril prevents cardiovascular events in high risk diabetic participants: Results of the HOPE study 2000
Randomized comparison of vasoflux, a novel anticoagulant, and heparin as adjunctive therapy to streptokinase for acute myocardial infarction 2000
Reduction of events by ramipril in high risk subjects is largely unrelated to blood pressure decrease 2000
Stent implantation in proximal left anterior descending coronary disease is associated with improved 30-day, 1 and 3-year outcomes 2000
Substantial benefit of hirudin compared to heparin among unstable angina patients undergoing early percutaneous coronary intervention 2000
The extent of ischemic and non-ischemic viable tissue predicts the degree of recovery of LV dysfunction post-revascularization 2000
The long-term predictive value of peak oxygen intake in 12,169 men referred for cardiac rehabilitation 2000
Time-to-balloon dependence of coronary flow velocity reserve after primary angioplasty in patients with anterior acute myocardial infarction 2000
Discussion 1998
Evaluation of the Myocardial Venous Blood Oxygen Level Changes Using MRI 1998
Feasibility of a New Non Invasive Method for the Evaluation of Coronary Blood Flow in the Left Anterior Descending Coronary Artery: Contrast-enhanced Transthoracic Harmonic Echo Doppler 1998
Incidence, Predictive Factors and Prognostic Significance of Supraventricular Tachyarrhythmias in Congestive Heart Failure 1998
Increased Insulin and Glucose Levels in Heart Failure (HF) 1998
Randomized Controlled Trial of Exercise Training in Patients With Congestive Heart Failure (EXERT) 1998
Seasonal Occurrence of Acute Myocardial Infarction in the National Registry of Myocardial Infarction-2 (NRMI-2) 1998
The Association Between Cardiac Rupture and Early Mortality Among Women With Myocardial Infarction Treated With Thrombolytics 1998
The Impact of Time to Thrombolytic Therapy on Outcome in Patients With Acute Myocardial Infarction (AMI) 1998
Antecedent angina pectoris and in-hospital outcome after myocardial infarction in patients receiving thrombolytic therapy: The second national registry of myocardial infarction (NRMI 2) 1997
Does cardiac rupture represent a hemorrhagic complication of thrombolytic therapy and thrombin inhibition? 1997
Enoxaparin suppresses platelet-dependent thrombin generation in vivo among patients with unstable angina and non-Q-wave myocardial infarction 1997
Hemorrhage incidence with low molecular weight heparin vs unfractionated heparin in patients with unstable angina or non-Q-wave myocardial infarction 1997
Improved measurement of myocardial venous blood oxygen level with magnetic resonance imaging 1997
LV dysfunction after open repair of simple defects in infants and children: Quantitation with a conductance catheter after bypass 1997
INCLUSION OF PATIENTS ONLY WITH LOW EJECTION FRACTION IN HEART-FAILURE TRIAL BIASES THE POPULATION AGAINST WOMEN AND THE ELDERLY 1994
LEFT-VENTRICULAR VOLUMES PREDICT DEVELOPMENT OF HEART-FAILURE AND POTENTIAL CLINICAL UTILITY OF ACE-INHIBITORS IN PATIENTS WITH ASYMPTOMATIC SYSTOLIC DYSFUNCTION 1994
MAGNETIC-RESONANCE ANGIOGRAPHY OF CORONARY-ARTERIES - A 2-DIMENSIONAL VERSUS 3-DIMENSIONAL APPROACH 1994
PLASMA NOREPINEPHRINE AND ATRIAL-NATRIURETIC-PEPTIDE LEVELS PREDICT PROGNOSIS IN PATIENTS WITH ASYMPTOMATIC LEFT-VENTRICULAR DYSFUNCTION 1994
WOMEN ARE AT HIGHER RISK FOR EARLY CORONARY-ARTERY BYPASS GRAFT CLOSURE 1994
COMPARATIVE NEUROHORMONAL RESPONSES IN PATIENTS WITH PRESERVED AND IMPAIRED LEFT-VENTRICULAR EJECTION FRACTION - RESULTS OF THE STUDIES OF LEFT-VENTRICULAR DYSFUNCTION (SOLVD) REGISTRY 1993
CURRENT AND ONGOING RANDOMIZED TRIALS IN HEART-FAILURE AND LEFT-VENTRICULAR DYSFUNCTION 1993
Measurement of health-related quality of life in heart failure 1993
NATURAL-HISTORY AND PATTERNS OF CURRENT PRACTICE IN HEART-FAILURE 1993
Assessment of clinical outcome in heart failure: Discussion IX 1993
Epidemiology: Discussion I 1993
Neurohormonal inhibitors: Discussion VII 1993
Positive inotropic agents: Discussion V 1993
DO BASE-LINE CLINICAL CHARACTERISTICS PREDICT INITIAL RESPONSE TO ANTIARRHYTHMIC THERAPY 1987
EFFECT OF ACUTE OR CHRONIC ADMINISTRATION OF CALCIUM-ANTAGONISTS ON MORTALITY FOLLOWING MYOCARDIAL-INFARCTION 1987
DIFFERENTIAL EFFECT OF BETA-BLOCKADE ON THE INNERVATED AND DENERVATED HUMAN-HEART DURING EXERCISE AND EXOGENOUS CATECHOLAMINE STIMULATION 1986
MECHANISM OF CARDIAC-OUTPUT INCREASE DURING DYNAMIC EXERCISE IN CARDIAC TRANSPLANT PATIENTS 1986
INCREASED SENSITIVITY OF THE DENERVATED HUMAN-HEART TO ISOPRENALINE BEFORE AND AFTER BETABLOCKADE 1985
ECHOCARDIOGRAPHIC RECOGNITION OF MYOCARDIAL SCARS IN PREMATURE-INFANTS 1984
EXERCISE AFTER MYOCARDIAL-INFARCTION REDUCES MORTALITY - EVIDENCE FROM RANDOMIZED CONTROLLED TRIALS (RCTS) 1984
EFFICACY OF INTRAVENOUS STREPTOKINASE DURING ACUTE MYOCARDIAL-INFARCTION - POOLED RESULTS FROM RANDOMIZED TRIALS 1983
REDUCTION IN INFARCT SIZE, MORBIDITY AND SHORT-TERM MORTALITY BY EARLY INTRAVENOUS BETABLOCKADE 1983
A Guide to Implementation Science for Phase 3 Clinical Trialists: Designing Trials for Evidence Uptake.. 84:2063-2072. 2024
Heart Failure Risk Assessment Using Biomarkers in Patients With Atrial Fibrillation: Analysis From COMBINE-AF.. 84:1528-1540. 2024
International Clinical Practice Guideline Recommendations for Acute Pulmonary Embolism: Harmony, Dissonance, and Silence.. 84:1561-1577. 2024
2024 Update to the 2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure: A Report of the American Heart Association/American College of Cardiology Joint Committee on Performance Measures.. 84:1123-1143. 2024
Antithrombotic Strategies for Patients With Peripheral Artery Disease: JACC Scientific Statement.. 84:936-952. 2024
Low-Dose Rivaroxaban Plus Aspirin in Fragile Patients After Lower Extremity Revascularization.. 84:801-811. 2024
Apixaban vs Aspirin According to CHA2DS2-VASc Score in Subclinical Atrial Fibrillation. 84:354-364. 2024
Coronary Artery Bypass Graft Failure in Women. 84:182-191. 2024
Addressing the Global Burden of Cardiovascular Disease in Women. 83:2690-2707. 2024
EFFICACY AND SAFETY OF DUAL ANTIPLATELET THERAPY AFTER ERIPHERAL ARTERY REVASCULARIZATION: INSIGHTS FROM VOYAGER PAD. 83:2213-2213. 2024
EFFICACY OF RIVAROXABAN IN REDUCING CORONARY OR PERIPHERAL HOSPITALIZATIONS ACCORDING TO SMOKING STATUS: A POST HOC ANALYSIS OF THE VOYAGER PAD TRIAL. 83:2285-2285. 2024
PROPHYLACTIC ATRIAL ABLATION DURING CARDIAC SURGERY TO PREVENT ATRIAL FIBRILLATION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED TRIALS. 83:132-132. 2024
RISK OF ADVERSE EVENTS IN PERIPHERAL ARTERY DISEASE PATIENTS WITH BELOW-KNEE DISEASE: AN ANALYSIS FROM THE VOYAGER-PAD CATHETER-BASED ANGIOGRAPHIC CORE LAB. 83:2216-2216. 2024
Bleeding Outcomes in Patients Treated With Asundexian in Phase II Trials. 83:669-678. 2024
Reply. 83:e49-e49. 2024
When Direct Oral Anticoagulants Should Not Be Standard Treatment. 83:444-465. 2024
Global Burden of Cardiovascular Diseases and Risks, 1990-2022. 82:2350-2473. 2023
Safety and Efficacy of Renal Denervation in Patients Taking Antihypertensive Medications. 82:1809-1823. 2023
TCT-243 Early Risk of Major Adverse Limb Events Following Lower Extremity Revascularization in the VOYAGER-PAD Trial. 82:B95-B95. 2023
TCT-251 A Systematic Review and Meta-Analysis of the Effect of Pre-hospital ECG Transmission for ST-Segment Elevation Myocardial Infarction Patients on Door-to-Device Time and Mortality. 82:B98-B99. 2023
TCT-296 Ultrasound-Guided Transfemoral Access for Coronary Procedures: A Pooled Learning Curve Analysis of the FAUST and UNIVERSAL Trials. 82:B117-B118. 2023
TCT-623 Effects of Complete Revascularization in Relation to Left Ventricular Function in Patients With STEMI and Multivessel Disease: Data from the COMPLETE Randomized trial. 82:B250-B251. 2023
Validation of Risk Stratification for Cardiac Events in Pregnant Women With Valvular Heart Disease. 82:1395-1406. 2023
Perioperative Myocardial Injury/Infarction After Cardiac Surgery. 82:1313-1315. 2023
Bridging Treatment Implementation Gaps in Patients With Heart Failure. 82:544-558. 2023
Team-Based Virtual Nudges to Overcome Clinician Inertia in Guideline-Directed Medical Therapy for Heart Failure. 81:1694-1696. 2023
30-DAY AND 1-YEAR MORTALITY IN A 4-YEAR POPULATION-BASED COHORT: ASSOCIATIONS WITH NATRIURETIC PEPTIDE TYPE AND PREVIOUS HEART FAILURE DIAGNOSIS. 81:651-651. 2023
CONSISTENT BENEFIT OF RIVAROXABAN EARLY AND LATE AFTER LOWER EXTREMITY REVASCULARIZATION. 81:2015-2015. 2023
Integrating Psychosocial Care in the Management of Patients With Vascular Disease. 81:1201-1204. 2023
Warfarin Is the Preferred Therapy for Patients With Thrombotic APS. 81:31-33. 2023
Edoxaban for Thromboembolism Prevention in Pediatric Patients With Cardiac Disease. 80:2301-2310. 2022
Canadian Spontaneous Coronary Artery Dissection Cohort Study. 80:1585-1597. 2022
Reply. 80:e51-e51. 2022
Incorporating Cultural Competence and Cultural Humility in Cardiovascular Clinical Trials to Increase Diversity Among Participants. 80:89-92. 2022
Primary Composite Outcome in PRAGUE-17. 79:e497-e497. 2022
Underutilization of Guideline-Directed Medical Therapy in Heart Failure. 79:2214-2218. 2022
Elevated Lipoprotein(a) and Risk of Atrial Fibrillation. 79:1579-1590. 2022
Trends in National Institutes of Health R01 Funding of Principal Investigators in Cardiology by Gender. 79:1544-1546. 2022
BENEFITS OF RIVAROXABAN AFTER LOWER EXTREMITY REVASCULARIZATION FOR SYMPTOMATIC PERIPHERAL ARTERY DISEASE ARE CONSISTENT WITH AND WITHOUT BACKGROUND STATIN THERAPY. 79:1747-1747. 2022
Lipoprotein(a) Cholesterol Masquerading as Low-Density Lipoprotein Cholesterol. 79:1047-1049. 2022
PATTERNS OF NATRIURETIC PEPTIDE ADOPTION IN ONTARIO, CANADA: A POPULATION-BASED ANALYSIS. 79:435-435. 2022
RHYTHM VERSUS RATE CONTROL IN PATIENTS WITH POSTOPERATIVE ATRIAL FIBRILLATION FOLLOWING CARDIAC SURGERY: A SYSTEMATIC REVIEW AND META-ANALYSIS. 79:44-44. 2022
RIVAROXABAN REDUCES HOSPITALIZATIONS FOR THROMBOEMBOLIC EVENTS IN PATIENTS WITH PERIPHERAL ARTERY DISEASE AFTER REVASCULARIZATION IN THOSE WITH AND WITHOUT CHRONIC KIDNEY DISEASE. 79:1739-1739. 2022
THE BURDEN OF UNCONTROLLED CARDIOVASCULAR RISK FACTORS IN MEN WITH PROSTATE CANCER: A RADICAL PC ANALYSIS. 79:1892-1892. 2022
USE OF DUAL PATHWAY INHIBITION FOR SECONDARY PREVENTION IN PATIENTS WITH ATHEROTHROMBOTIC DISEASE: THE PROSPECTIVE REAL-WORLD XATOA STUDY. 79:1746-1746. 2022
WALKING IMPAIRMENT IN PATIENTS WITH SYMPTOMATIC PERIPHERAL ARTERY DISEASE AFTER LOWER EXTREMITY REVASCULARIZATION. 79:1774-1774. 2022
Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization. 78:1768-1778. 2021
Reply. 78:e91-e92. 2021
Colchicine in Patients With Chronic Coronary Disease in Relation to Prior Acute Coronary Syndrome. 78:859-866. 2021
Factor XI Inhibition to Uncouple Thrombosis From Hemostasis. 78:625-631. 2021
Global Chronic Total Occlusion Crossing Algorithm. 78:840-853. 2021
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. 78:421-433. 2021
Rivaroxaban in Patients With Recent Peripheral Artery Revascularization and Renal Impairment. 78:757-759. 2021
Is it Time for Sex-Specific Guidelines for Cardiovascular Disease?. 78:189-192. 2021
Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease. 78:14-23. 2021
Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial. 78:317-326. 2021
Correction. 77:2760-2760. 2021
Ending Gender Inequality in Cardiovascular Clinical Trial Leadership. 77:2960-2972. 2021
Prevalence of Left Atrial Thrombus in Anticoagulated Patients With Atrial Fibrillation. 77:2875-2886. 2021
Reply. 77:2757-2757. 2021
ANDEXANET ALFA FOR ACUTE BLEEDING DURING TREATMENT WITH ENOXAPARIN. 77:1856-1856. 2021
EFFICACY AND SAFETY OF LOW-DOSE RIVAROXABAN IN SYMPTOMATIC PAD PATIENTS UNDERGOING REVASCULARIZATION CURRENTLY SMOKING: INSIGHTS FROM VOYAGER PAD. 77:1808-1808. 2021
EFFICACY AND SAFETY OF RIVAROXABAN IN ELDERLY PATIENTS WITH SYMPTOMATIC PAD UNDERGOING REVASCULARIZATION: INSIGHTS FROM VOYAGER PAD. 77:1783-1783. 2021
Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19. 77:1903-1921. 2021
Impact of Obesity on Outcomes of Pregnancy in Women With Heart Disease. 77:1317-1326. 2021
Intracranial Atherosclerotic Plaque and Embolic Stroke of Undetermined Source. 77:692-694. 2021
Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial. 77:511-525. 2021
International Impact of COVID-19 on the Diagnosis of Heart Disease. 77:173-185. 2021
The Indirect Consequences of the Response to the COVID-19 Pandemic. 77:186-188. 2021
Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019. 76:2982-3021. 2020
Plasma Apixaban Levels in Patients Treated Off Label With the Lower Dose. 76:2906-2907. 2020
Characteristics of Heart Failure Trials Associated With Under-Representation of Women as Lead Authors. 76:1919-1930. 2020
Influenza Vaccination to Reduce Cardiovascular Morbidity and Mortality in Patients With COVID-19. 76:1777-1794. 2020
Nonculprit Lesion Severity and Outcome of Revascularization in Patients With STEMI and Multivessel Coronary Disease. 76:1277-1286. 2020
Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI. 76:1468-1483. 2020
2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. 76:594-622. 2020
Saturated Fats and Health: A Reassessment and Proposal for Food-Based Recommendations. 76:844-857. 2020
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. 75:2950-2973. 2020
Impact of Beta-Blockers on Birth Weight in a High-Risk Cohort of Pregnant Women With CVD. 75:2751-2752. 2020
Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients. 75:3140-3147. 2020
Evolocumab in HIV-Infected Patients With Dyslipidemia. 75:2570-2584. 2020
Randomized Trials in Cardiac Surgery. 75:1593-1604. 2020
Optimal Prescription of the Lower Dose of Apixaban. 75:1156-1158. 2020
Preventing Complications in Pregnant Women With Cardiac Disease. 75:1443-1452. 2020
Limitations of Repeat Revascularization as an Outcome Measure. 74:3164-3173. 2019
Timing of Staged Nonculprit Artery Revascularization in Patients With ST-Segment Elevation Myocardial Infarction. 74:2713-2723. 2019
Five Issues With the Cardiovascular Risk Index. 74:2327-2328. 2019
Are Ticks the Answer to Medical Device-Associated Clotting?. 74:2190-2192. 2019
Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment. 74:1760-1768. 2019
Preventing Alzheimer’s Disease. 74:1924-1925. 2019
Machine Learning Could Facilitate Optimal Titration of Guideline-Directed Medical Therapy in Heart Failure. 74:1424-1425. 2019
Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin. 74:1519-1528. 2019
Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction. 74:601-612. 2019
From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5). 74:683-698. 2019
The Evolution of β-Blockers in Coronary Artery Disease and Heart Failure (Part 1/5). 74:672-682. 2019
Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial. 73:3271-3280. 2019
Monitoring Emerging Data From the COMPASS Trial of an Antithrombotic Agent. 73:2769-2772. 2019
Perspective on Emerging Evidence in the Repair of Intact Descending Thoracic Aortic Aneurysms. 73:3036-3037. 2019
Pre- and post-treatment with amiodarone for elective electrical cardioversion of atrial fibrillation: a systematic review and meta-analysis. 21:856-863. 2019
Reply. 73:2360-2360. 2019
Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction. 73:2243-2250. 2019
Lifestyle, Glycosylated Hemoglobin A1c, and Survival Among Patients With Stable Ischemic Heart Disease and Diabetes. 73:2049-2058. 2019
A Call for Randomized Trials of Oral Anticoagulation for Patients With Post-Operative Atrial Fibrillation. 73:1105-1105. 2019
Relationships of Overt and Silent Brain Lesions With Cognitive Function in Patients With Atrial Fibrillation. 73:989-999. 2019
Reply. 73:532-532. 2019
Association of the PHACTR1/EDN1 Genetic Locus With Spontaneous Coronary Artery Dissection. 73:58-66. 2019
Linking Spontaneous Coronary Artery Dissection, Cervical Artery Dissection, and Fibromuscular Dysplasia. 73:67-69. 2019
Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion. 73:121-130. 2019
Healthy Behavior, Risk Factor Control, and Survival in the COURAGE Trial. 72:2297-2305. 2018
Cardiac Outcomes in Pregnant Women With Treated Cancer. 72:2087-2089. 2018
Pathology of Peripheral Artery Disease in Patients With Critical Limb Ischemia. 72:2152-2163. 2018
Thrombus Aspiration in Patients With High Thrombus Burden in the TOTAL Trial. 72:1589-1596. 2018
TCT-56 High-resolution Intravascular OCT-NIRF Molecular Imaging for In Vivo Assessment of Inflammation in Atherosclerosis and Vascular Injury. 72:B25-B25. 2018
Are NSAIDs Double Trouble?. 72:268-270. 2018
Blood CSF1 and CXCL12 as Causal Mediators of Coronary Artery Disease. 72:300-310. 2018
Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation. 72:255-267. 2018
Direct Oral Anticoagulants and Myocardial Infarction. 72:27-28. 2018
Global Prospective Safety Analysis of Rivaroxaban. 72:141-153. 2018
Stroke Prevention in Atrial Fibrillation. 72:154-155. 2018
Progression of Device-Detected Subclinical Atrial Fibrillation and the Risk of Heart Failure. 71:2603-2611. 2018
Reduced-Intensity Anticoagulation for Mechanical Aortic Valve Prostheses. 71:2727-2730. 2018
Antithrombotic Therapy for Peripheral Artery Disease. 71:2450-2467. 2018
Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease. 71:2306-2315. 2018
Resolving Concerns With the Newer Oral Anticoagulant Medications. 71:1114-1116. 2018
Compliance With Guideline-Directed Medical Therapy in Contemporary Coronary Revascularization Trials. 71:591-602. 2018
Identifying and Treating Young Patients at Risk for Cardiovascular Events. 71:303-305. 2018
2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. 70:3042-3067. 2017
A Test in Context: D-Dimer. 70:2411-2420. 2017
Fondaparinux for Treatment of Heparin-Induced Thrombocytopenia. 70:2649-2651. 2017
Physical Activity and Mortality in Patients With Stable Coronary Heart Disease. 70:1689-1700. 2017
Inferior Vena Cava Filters to Prevent Pulmonary Embolism. 70:1587-1597. 2017
Optimizing Cholesterol Treatment in Patients With Muscle Complaints. 70:1290-1301. 2017
Persistence With Dabigatran Therapy at 2 Years in Patients With Atrial Fibrillation. 70:1573-1583. 2017
Frailty in Older Adults Undergoing Aortic Valve Replacement. 70:689-700. 2017
Survival After Isolated Post-Operative Troponin Elevation. 70:907-908. 2017
Should the AKI-MATRIX Trial Change Our Practice? ∗. 69:2604-2605. 2017
Effect of Current Dietary Recommendations on Weight Loss and Cardiovascular Risk Factors.. 69:1103-1112. 2017
Adherence to Healthy Lifestyle and Cardiovascular Diseases in the Chinese Population. 69:1116-1125. 2017
Effect of Current Dietary Recommendations on Weight Loss and Cardiovascular Risk Factors. 69:1103-1112. 2017
WORLDWIDE VARIATION IN THE USE OF NUCLEAR CARDIOLOGY CAMERA TECHNOLOGY, RECONSTRUCTION SOFTWARE, AND ACQUISITION PROTOCOLS: FINDINGS FROM THE IAEA NUCLEAR CARDIOLOGY PROTOCOLS STUDY (INCAPS). 69:1587-1587. 2017
Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers. 69:939-947. 2017
Coronary Artery Bypass Grafting With and Without Manipulation of the Ascending Aorta. 69:924-936. 2017
The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2. 69:777-785. 2017
Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention. 69:176-185. 2017
Prosthetic Heart Valve Thrombosis. 68:2671-2689. 2016
Prosthetic Heart Valve Thrombosis. 68:2670-2689. 2016
GW27-e0256 Panax quinquefolium saponin combined with dual antiplatelet drugs inhibits platelet adhesion to injured HUVECs via PI3K/AKT and COX pathways. 68:C8-C8. 2016
How Robust Is the Evidence for Recommending Very Low Salt Intake in Entire Populations? ∗. 68:1618-1621. 2016
Assessing the Impact of Medication Adherence on Long-Term Cardiovascular Outcomes. 68:789-801. 2016
IMPACT OF A PHYSICIAN-GUIDED VERSUS STANDARD MINIMUM 24 HOUR CORONARY CARE UNIT STAY ON OUTCOMES IN STABLE PATIENTS WHO HAVE RECEIVED PRIMARY PERCUTANEOUS CORONARY INTERVENTION FOR ST-ELEVATION MYOCARDIAL INFARCTION. 67:570-570. 2016
Telomere Length and Risk of Myocardial Infarction in a MultiEthnic Population. 67:1863-1865. 2016
Clinically Significant Pocket Hematoma Increases Long-Term Risk of Device Infection. 67:1300-1308. 2016
Reply. 66:2682-2682. 2015
RESPONSE: Why Are Population Health, Health Systems, and Clinical Medicine Equally Important?. 66:2262-2262. 2015
Correction. 66:2269-2269. 2015
Correction. 66:1948-1948. 2015
Food Consumption and its Impact on Cardiovascular Disease: Importance of Solutions Focused on the Globalized Food System. 66:1590-1614. 2015
Outcomes of Cancer Patients Undergoing Percutaneous Pericardiocentesis for Pericardial Effusion. 66:1119-1128. 2015
Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis. 66:1236-1246. 2015
Changes in Renal Function in Patients With Atrial Fibrillation. 65:2481-2493. 2015
Global Cardiovascular Research Training for Implementation Science, Health Systems Research, and Health Policy Research. 65:1371-1372. 2015
ANNEXATM-R: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, DEMONSTRATING REVERSAL OF RIVAROXABAN-INDUCED ANTICOAGULATION IN OLDER SUBJECTS BY ANDEXANET ALFA (PRT064445), A UNIVERSAL ANTIDOTE FOR FACTOR XA (FXA) INHIBITORS. 65:A23-A23. 2015
Cost Effectiveness of Continued-Warfarin Versus Heparin-Bridging Therapy During Pacemaker and Defibrillator Surgery. 65:957-959. 2015
Noncorticosteroid Immunosuppression Limits Myocardial Damage and Contractile Dysfunction in Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss Syndrome). 65:103-105. 2015
Cardiovascular Disease in Asian Americans. 64:2495-2497. 2014
Vorapaxar, Combination Antiplatelet Therapy, and Stroke∗. 64:2327-2329. 2014
Immature Platelet Count. 64:2130-2132. 2014
Laboratory Measurement of the Anticoagulant Activity of the Non–Vitamin K Oral Anticoagulants. 64:1128-1139. 2014
Worsening Renal Function and Outcome in Heart Failure Patients With Preserved Ejection Fraction and the Impact of Angiotensin Receptor Blocker Treatment. 64:1106-1113. 2014
Switching Patients From Blinded Study Drug to Warfarin at the End of the ENGAGE AF–TIMI 48 Trial. 64:585-587. 2014
Alcohol Consumption and Risk of Atrial Fibrillation. 64:290-292. 2014
Reply. 63:2885-2886. 2014
Reply: regarding the effect of dabigatran plasma concentrations.. 63:2885-2886. 2014
Comparison of Diagnostic Accuracy of Combined Assessment Using Adenosine Stress Computed Tomography Perfusion + Computed Tomography Angiography With Transluminal Attenuation Gradient + Computed Tomography Angiography Against Invasive Fractional Flow Reserve. 63:1904-1912. 2014
Invasively Assessed Coronary Flow Dynamics Improve Following Relief of Aortic Stenosis With Transcatheter Aortic Valve Implantation. 63:1808-1809. 2014
Polypills. 63:1368-1370. 2014
Procedural Volume and Outcomes With Radial or Femoral Access for Coronary Angiography and Intervention. 63:954-963. 2014
Left Atrial Appendage Occlusion. 63:291-298. 2014
The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients. 63:321-328. 2014
The Prognostic Value of Pre-Operative and Post-Operative B-Type Natriuretic Peptides in Patients Undergoing Noncardiac Surgery. 63:170-180. 2014
Treatment Goals of Pulmonary Hypertension. 62:D73-D81. 2013
Clinical Characteristics and Outcomes of Young and Very Young Adults With Heart Failure. 62:1845-1854. 2013
Low Levels of High-Density Lipoprotein Cholesterol and Increased Risk of Cardiovascular Events in Stable Ischemic Heart Disease Patients. 62:1826-1833. 2013
Secretory Phospholipase A2-IIA and Cardiovascular Disease. 62:1966-1976. 2013
Predictive Factors, Management, and Clinical Outcomes of Coronary Obstruction Following Transcatheter Aortic Valve Implantation. 62:1552-1562. 2013
Balancing the Benefits and Risks of 2 Doses of Dabigatran Compared With Warfarin in Atrial Fibrillation. 62:900-908. 2013
Risk Factor Control for Coronary Artery Disease Secondary Prevention in Large Randomized Trials. 61:1607-1615. 2013
Transluminal Attenuation Gradient in Coronary Computed Tomography Angiography Is a Novel Noninvasive Approach to the Identification of Functionally Significant Coronary Artery Stenosis. 61:1271-1279. 2013
Effect of Atrial Fibrillation on Atrial Thrombogenesis in Humans: Impact of Rate and Rhythm. 61:852-860. 2013
Low-Dose Colchicine for Secondary Prevention of Cardiovascular Disease. 61:404-410. 2013
6-Min Walk Test Provides Prognostic Utility Comparable to Cardiopulmonary Exercise Testing in Ambulatory Outpatients With Systolic Heart Failure. 60:2653-2661. 2012
Effects of Radial Versus Femoral Artery Access in Patients With Acute Coronary Syndromes With or Without ST-Segment Elevation. 60:2490-2499. 2012
Assessing the Association of Appropriateness of Coronary Revascularization and Clinical Outcomes for Patients With Stable Coronary Artery Disease. 60:1876-1884. 2012
Long-Term Outcomes After Transcatheter Aortic Valve Implantation. 60:1864-1875. 2012
Quantification of Absolute Myocardial Perfusion in Patients With Coronary Artery Disease. 60:1546-1555. 2012
Type 2 Diabetes Mellitus and Risk of Incident Atrial Fibrillation in Women. 60:1421-1428. 2012
Cardiac Magnetic Resonance and the Need for Routine Cardiac Catheterization in Single Ventricle Patients Prior to Fontan: A Comparison of 3 Groups. 60:1094-1102. 2012
Prevention of Thromboembolic Events After Bioprosthetic Aortic Valve Replacement. 60:978-980. 2012
Impact of Metabolic Syndrome on Progression of Aortic Stenosis. 60:216-223. 2012
Association of Heart Rate and Outcomes in a Broad Spectrum of Patients With Chronic Heart Failure. 59:1785-1795. 2012
A Hungry Thrombus. 59:e29-e29. 2012
Dichotomizing High-Sensitivity Cardiac Troponin T Results and Important Analytical Considerations. 59:1570-1570. 2012
New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes. 59:1413-1425. 2012
Efficacy and Safety of Dabigatran Compared to Warfarin in Patients With Paroxysmal, Persistent, and Permanent Atrial Fibrillation. 59:854-855. 2012
Safety and Efficacy of Low Blood Pressures Among Patients With Diabetes. 59:74-83. 2012
Effects of Beta-Adrenergic Antagonists in Patients With Chronic Kidney Disease. 58:1152-1161. 2011
Overexpression of the Multidrug Resistance Protein-4 Transporter in Patients Undergoing Coronary Artery Bypass Graft Surgery. 58:762-764. 2011
Prevalence and Characteristics of Early Repolarization in the CASPER Registry. 58:722-728. 2011
Impact of Metabolic Syndrome and Diabetes on Prognosis and Outcomes With Early Percutaneous Coronary Intervention in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) Trial. 58:131-137. 2011
Alcohol Consumption and Risk of Atrial Fibrillation. 57:2545-2545. 2011
Meta-Analysis and Systematic Review of the Long-Term Predictive Value of Assessment of Coronary Atherosclerosis by Contrast-Enhanced Coronary Computed Tomography Angiography. 57:2426-2436. 2011
Pericardial Fat Is Associated With Atrial Fibrillation Severity and Ablation Outcome. 57:1745-1751. 2011
Parental History and Myocardial Infarction Risk Across the World. 57:619-627. 2011
Lack of Association Between the Trp719Arg Polymorphism in Kinesin-Like Protein-6 and Coronary Artery Disease in 19 Case-Control Studies. 56:1552-1563. 2010
Randomized, Controlled Trial of Individualized Heparin and Protamine Management in Infants Undergoing Cardiac Surgery With Cardiopulmonary Bypass. 56:1794-1802. 2010
Reply. 56:1356-1356. 2010
Metabolic Syndrome and Risk of Acute Myocardial Infarction. 55:2390-2398. 2010
The Long- and Short-Term Impact of Elevated Body Mass Index on the Risk of New Atrial Fibrillation. 55:2319-2327. 2010
Metabolic Syndrome Is Associated With More Pronounced Impairment of Left Ventricle Geometry and Function in Patients With Calcific Aortic Stenosis. 55:1867-1874. 2010
HEART FAILURE WITH PRESERVED EJECTION FRACTION: MORTALITY RISK POST FIRST HOSPITALIZATION - DATA FROM I-PRESERVE. 55:A141.E1321-A141.E1321. 2010
Intensive Multifactorial Intervention for Stable Coronary Artery Disease. 55:1348-1358. 2010
LOW-DOSE ACETYLSALICYLIC ACID-ASSOCIATED PEPTIC ULCERS AND DYSPEPTIC SYMPTOMS ARE REDUCED BY ESOMEPRAZOLE 20 MG AND 40 MG ONCE DAILY. 55:A56.E536-A56.E536. 2010
Prognostic Value of 64-Slice Cardiac Computed Tomography. 55:1017-1028. 2010
Transcatheter Aortic Valve Implantation for the Treatment of Severe Symptomatic Aortic Stenosis in Patients at Very High or Prohibitive Surgical Risk. 55:1080-1090. 2010
Evaluation of Early Complications Related to De Novo Cardioverter Defibrillator Implantation. 55:774-782. 2010
Progression From Paroxysmal to Persistent Atrial Fibrillation. 55:725-731. 2010
Peripheral Blood Monocyte Subset Assessment in Non–ST-Segment Elevation Myocardial Infarction Is Required. 55:169-169. 2010
Reply. 55:168-169. 2010
Cardiac Magnetic Resonance Findings in Congenitally Absent Pericardium. 54:2459-2459. 2009
Management of Platelet-Directed Pharmacotherapy in Patients With Atherosclerotic Coronary Artery Disease Undergoing Elective Endoscopic Gastrointestinal Procedures. 54:2261-2276. 2009
The Relative Efficacy and Safety of Clopidogrel in Women and Men. 54:1935-1945. 2009
Is a Pre-Operative Brain Natriuretic Peptide or N-Terminal Pro–B-Type Natriuretic Peptide Measurement an Independent Predictor of Adverse Cardiovascular Outcomes Within 30 Days of Noncardiac Surgery?. 54:1599-1606. 2009
Optimal Medical Therapy With or Without Percutaneous Coronary Intervention in Older Patients With Stable Coronary Disease. 54:1303-1308. 2009
Dual Renin-Angiotensin System Blockade in Heart Failure. 54:278-278. 2009
Efficacy and Safety of Fondaparinux Versus Enoxaparin in Patients With Acute Coronary Syndromes Treated With Glycoprotein IIb/IIIa Inhibitors or Thienopyridines. 54:468-476. 2009
Effect of Ramipril and of Rosiglitazone on Carotid Intima-Media Thickness in People With Impaired Glucose Tolerance or Impaired Fasting Glucose. 53:2028-2035. 2009
Reply. 53:2312-2313. 2009
Atrial Fibrillation and Heart Failure in Cardiology Practice: Reciprocal Impact and Combined Management From the Perspective of Atrial Fibrillation. 53:1690-1698. 2009
Safety and Effectiveness of Drug-Eluting and Bare-Metal Stents for Patients With Off- and On-Label Indications. 53:1773-1782. 2009
Lipid Profile, Plasma Apolipoproteins, and Risk of a First Myocardial Infarction Among Asians. 53:244-253. 2009
Clinical Outcomes According to Baseline Blood Pressure in Patients With a Low Ejection Fraction in the CHARM (Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity) Program. 52:2000-2007. 2008
The Pursuit of Clinically Relevant Measures of Platelet Function After Antiplatelet Drug Therapy⁎⁎Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. 52:1978-1980. 2008
Primary Prevention of Cardiovascular Mortality and Events With Statin Treatments. 52:1769-1781. 2008
Reply. 52:584-586. 2008
Clopidogrel Resistance. 51:1935-1937. 2008
SR123781A: A New Once-Daily Synthetic Oligosaccharide Anticoagulant for Thromboprophylaxis After Total Hip Replacement Surgery. 51:1498-1504. 2008
The perioperative ischemic evaluation (POISE) trial: A randomized controlled trial of metoprolol versus placebo in patients undergoing noncardiac surgery. 51:CS1-CS5. 2008
Revascularization for Unprotected Left Main Stem Coronary Artery Stenosis. 51:885-892. 2008
Combined Metabolomic and Proteomic Analysis of Human Atrial Fibrillation. 51:585-594. 2008
Effect of Intravenous Iron Sucrose on Exercise Tolerance in Anemic and Nonanemic Patients With Symptomatic Chronic Heart Failure and Iron Deficiency. 51:103-112. 2008
F-18-Fluorodeoxyglucose Positron Emission Tomography Imaging-Assisted Management of Patients With Severe Left Ventricular Dysfunction and Suspected Coronary Disease. 50:2002-2012. 2007
Incidence and Predictors of Hyperkalemia in Patients With Heart Failure. 50:1959-1966. 2007
Incidence of Stroke in Paroxysmal Versus Sustained Atrial Fibrillation in Patients Taking Oral Anticoagulation or Combined Antiplatelet Therapy. 50:2156-2161. 2007
Efficacy and Safety of Fondaparinux Versus Enoxaparin in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. 50:1742-1751. 2007
Red Cell Distribution Width as a Novel Prognostic Marker in Heart Failure. 50:40-47. 2007
Reply. 50:79-80. 2007
Amiodarone-Induced Thyrotoxicosis. 49:2350-2355. 2007
Diastolic Dysfunction in Heart Failure With Preserved Systolic Function: Need for Objective Evidence. 49:687-694. 2007
Gender-Related Differences in Presentation, Treatment, and Outcome of Patients With Atrial Fibrillation in Europe. 49:572-577. 2007
Rescue Angioplasty or Repeat Fibrinolysis After Failed Fibrinolytic Therapy for ST-Segment Myocardial Infarction. 49:422-430. 2007
Reply. 48:2357-2357. 2006
Atrial Fibrillation and Risk of Clinical Events in Chronic Heart Failure With and Without Left Ventricular Systolic Dysfunction. 47:1997-2004. 2006
Early Versus Delayed Enalapril in Patients With Left Ventricular Systolic Dysfunction: Impact on Morbidity and Mortality 15 Years After the SOLVD Trial. 47:1904-1905. 2006
Reply. 47:890-891. 2006
The Risk of Hemorrhage Among Patients With Warfarin-Associated Coagulopathy. 47:804-808. 2006
Differences in the Management and Prognosis of Women and Men Who Suffer From Acute Coronary Syndromes. 46:1845-1851. 2005
Sustained Benefit 20 Years After Reperfusion Therapy in Acute Myocardial Infarction. 46:15-20. 2005
Prevention of Atrial Fibrillation With Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers. 45:1832-1839. 2005
Relationship Between Carotid Artery Intima-Media Thickness and Brachial Artery Flow-Mediated Dilation in Middle-Aged Healthy Men. 45:1980-1986. 2005
Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. 45:838-845. 2005
Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. 45:391-399. 2005
Improvements in cardiac form and function after transcatheter closure of secundum atrial septal defects. 45:499-504. 2005
Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction. 43:2200-2206. 2004
1033-109 Assessing the need for repeat baseline exercise tests in heart failure patients: Early experience from HF-ACTION. 43:A167-A167. 2004
Dobutamine stress echocardiography for noninvasive assessment and risk stratification of patients with rheumatic mitral stenosis. 43:393-401. 2004
Peak oxygen intake and cardiac mortality in women referred for cardiac rehabilitation. 42:2139-2143. 2003
Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease. 42:1747-1753. 2003
Circadian variations in acute myocardial infarction. 41:2143-2146. 2003
American Heart Association/American College of Cardiology Foundation guide to warfarin therapy11The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.This statement has been co-published in the April 1, 2003, issue of Circulation.This statement was approved by the American Heart Association Science Advisory and Coordinating Committee in October 2002 and by the American College of Cardiology Board of Trustees in February 2003. A single reprint is available by calling 800-242-8721 (US only) or writing the American Heart Association, Public Information, 7272 Greenville Ave, Dallas, TX 75231-4596. Ask for reprint No. 71-0254. To purchase additional reprints: up to 999 copies, call 800-611-6083 (US only) or fax 413-665-2671; 1000 or more copies, call 410-528-4426, fax 410-528-4264, or e-mail klbradle@lww.com. To make photocopies for personal or educational use, call the Copyright Clearance Center, 978-750-8400.. 41:1633-1652. 2003
Aspirin resistance:a new independent predictor of vascular events?**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do no necessarily represent the views of JACCor the American College of Cardiology.. 41:966-968. 2003
The evolving role of direct thrombin inhibitors in acute coronary syndromes.. 41:70S-78S. 2003
Oral anticoagulants in patients with coronary artery disease. 41:S62-S69. 2003
Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention. 41:S79-S88. 2003
The evolving role of direct thrombin inhibitors in acute coronary syndromes. 41:S70-S78. 2003
Positron emission tomography and recovery following revascularization (PARR-1): the importance of scar and the development of a prediction rule for the degree of recovery of left ventricular function. 40:1735-1743. 2002
Effect of long-term therapy with ramipril in high-risk women. 40:693-702. 2002
Vasopeptidase inhibition with omapatrilat in chronic heart failure: acute and long-term hemodynamic and neurohumoral effects. 39:2034-2041. 2002
Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. 39:463-470. 2002
The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis. 39:30-36. 2002
Do antioxidant vitamins protect against atherosclerosis? The proof is still lacking**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.. 38:1795-1798. 2001
Survival following coronary angioplasty versus coronary artery bypass surgery in anatomic subsets in which coronary artery bypass surgery improves survival compared with medical therapy. 38:1440-1449. 2001
Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study. 38:806-813. 2001
Tackling the growing epidemic of cardiovascular disease in South Asia∗∗Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.. 38:688-689. 2001
Risk prediction after myocardial infarction in the elderly∗∗Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.. 38:460-463. 2001
Progression to chronic atrial fibrillation after pacing: the Canadian Trial of Physiologic Pacing. 38:167-172. 2001
Overutilization and underutilization of thrombolysis in routine clinical practice∗∗Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.. 37:1588-1589. 2001
Relationship of current and past smoking to mortality and morbidity in patients with left ventricular dysfunction. 37:1677-1682. 2001
Reactivation of ischemic events in acute coronary syndromes: results from GUSTO-IIb. Gobal Use of Strategies To Open occluded arteries in acute coronary syndromes.. 37:1001-1007. 2001
Reactivation of ischemic events in acute coronary syndromes: results from GUSTO-IIb. 37:1001-1007. 2001
Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. 37:475-484. 2001
Impact of right ventricular involvement on mortality and morbidity in patients with inferior myocardial infarction11Drs. Mehta and Eikelboom were recipients of Heart and Stroke Foundation of Canada Research Fellowship Awards. Professor Yusuf is the recipient of a Medical Research Council of Canada Senior Scientist Award and holds a Heart and Stroke Foundation of Ontario Research Chair.. 37:37-43. 2001
Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease - One-year results of the ESSENCE study. 36:693-698. 2000
Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease∗∗∗∗A list of participating ESSENCE Study Group investigators may be found in N Engl J Med 1997;337:447–52.. 36:693-698. 2000
Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin. 35:1801-1807. 2000
Management of myocardial infarction: looking beyond efficacy∗∗Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.. 35:380-381. 2000
Twenty year trends (1975–1995) in the incidence, in-hospital and long-term death rates associated with heart failure complicating acute myocardial infarction. 34:1378-1387. 1999
ACC/AHA guidelines for coronary artery bypass graft surgery. 34:1262-1347. 1999
Thrombin generation after the abrupt cessation of intravenous unfractionated heparin among patients with acute coronary syndromes. 34:1020-1027. 1999
Validation of a new noninvasive method (contrast-enhanced transthoracic second harmonic echo Doppler) for the evaluation of coronary flow reserve. 34:1193-1200. 1999
Increased winter mortality from acute myocardial infarction and stroke: the effect of age. 33:1916-1919. 1999
Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia. 33:1286-1293. 1999
Relationship of glucose and insulin levels to the risk of myocardial infarction: a case-control study. 33:612-619. 1999
Fatal cardiac rupture among patients treated with thrombolytic agents and adjunctive thrombin antagonists. 33:479-487. 1999
The North American vasovagal pacemaker study (VPS). 33:16-20. 1999
Randomized Comparison of Direct Thrombin Inhibition Versus Heparin in Conjunction With Fibrinolytic Therapy for Acute Myocardial Infarction: Results From the GUSTO-IIb Trial. 31:1493-1498. 1998
Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators.. 31:1493-1498. 1998
Seasonal Distribution of Acute Myocardial Infarction in the Second National Registry of Myocardial Infarction 11The National Registry of Myocardial Infarction is supported by Genentech, Inc., South San Francisco, California. Genentech, Inc. reimburses ClinTrials Research, Inc. for the cost of data analysis and biostatistical services.. 31:1226-1233. 1998
Randomized controlled trial of exercise training in patients with congestive heart failure (EXERT). 31:508-509. 1998
Evaluation of the myocardial venous blood oxygen level changes using MRI. 31:164-165. 1998
Increased insulin and glucose levels in heart failure (HF). 31:249-249. 1998
Guidelines for Management of Left-Sided Prosthetic Valve Thrombosis: A Role for Thrombolytic Therapy 11These guidelines are the results of a Consensus Conference held during the Symposium on Prosthetic Valve Thrombosis on September 16, 1994, in Budapest, Hungary.. 30:1521-1526. 1997
Comparative Effects of Losartan and Enalapril on Exercise Capacity and Clinical Status in Patients With Heart Failure fn1fn1This study was supported by a grant from Merck Research Laboratories, West Point, Pennsylvania.. 30:983-991. 1997
Can Nitrogen-13 Ammonia Kinetic Modeling Define Myocardial Viability Independent of Fluorine-18 Fluorodeoxyglucose?. 29:537-543. 1997
Six-month effects of early treatment with lisinopril and transdermal glyceryl trinitrate singly and together withdrawn six weeks atter acute myocardial infarction: The GISSI-3 trial. 27:337-344. 1996
Abnormalities in intramyocardial arteries detected in cardiac transplant biopsy specimens and lack of correlation with abnormal intracoronary ultrasound or endothelial dysfunction in large epicardial coronary arteries. 26:110-119. 1995
AMERICAN-COLLEGE-OF-CARDIOLOGY, AMERICAN-COLLEGE OF RADIOLOGY AND INDUSTRY DEVELOP STANDARD FOR DIGITAL TRANSFER OF ANGIOGRAPHIC IMAGES. 25:800-802. 1995
Effects of exercise training in patients with congestive heart failure: A critical review. 25:789-796. 1995
407-5 Expression of a Mutation Causing Hypertrophic Cardiomyopathy Disrupts Sarcomere Assembly in Adult Feline Cardiac Myocytes. 25:2A-2A. 1995
986-79 Identification of Coronary Artery Disease and Assessment of Prognosis in Patients with Chronic Renal Failure: Role of Dobutamine Stress Echocardiography. 25:306A-306A. 1995
Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: A report from the registry of studies of left ventricular dysfunction. 23:1410-1420. 1994
Quality of life among 5,025 patients with left ventricular dysfunction randomized between placebo and enalapril: The studies of left ventricular dysfunction. 23:393-400. 1994
Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: Results of the studies of left ventricular dysfunctions (SOLVD) registry. 22:A146-A153. 1993
Current and ongoing randomized trials in heart failure and left ventricular dysfunction. 22:A194-A197. 1993
Discussion I. 22:A20-A21. 1993
Discussion IX. 22:A192-A193. 1993
Discussion V. 22:A127-A128. 1993
Discussion VII. 22:A162-A164. 1993
HEART-FAILURE IN THE 1990S - EVOLUTION OF A MAJOR PUBLIC-HEALTH PROBLEM IN CARDIOVASCULAR MEDICINE. 22:A3-A5. 1993
Heart failure in the 1990s: Evolutions of a major public health problem in cardiovascular medicine. 22:A3-A5. 1993
Measurement of health-related quality of life in heart failure.. 22:185A-191A. 1993
Natural history and patterns of current practice in heart failure. 22:A14-A19. 1993
Panel discussion I: Evaluation and management of chronic heart failure. 22:A201-A203. 1993
Discussion I. 22. 1993
Discussion IX. 22. 1993
Discussion V. 22. 1993
Discussion VII. 22. 1993
Effect of amiodarone on mortality after myocardial infarction: A double-blind, placebo-controlled, pilot study. 20:1056-1062. 1992
INVITRO HIGH-RESOLUTION INTRAVASCULAR IMAGING IN MUSCULAR AND ELASTIC ARTERIES. 20:153-160. 1992
In vitro high resolution intravascular imaging in muscular and elastic arteries. 20:153-160. 1992
Canadian atrial fibrillation anticoaguiation (CAFA) study. 18:349-355. 1991
Coronary patency, infarct size and left ventricular function after thrombolytic therapy for acute myocardial infarction: results from the tissue plasminogen activator: Toronto (TPAT) placebo-controlled trial. 17:1451-1457. 1991
Exercise training improves metabolism of skeletal muscle in patients with stable heart failure. 17:A159-A159. 1991
Tissue plasminogen activator: Toronto (TPAT) placebo-controlled randomized trial in acute myocardial infarction. 13:1469-1476. 1989
Randomized placebo-controlled trial of propafenone for treatment of atrial tachyarrhythmias after cardiac surgery. 10:1145-1148. 1987
CLINICAL-FEATURES AND DIAGNOSIS OF VENOUS THROMBOSIS. 8:B114-B127. 1986
Clinical features and diagnosis of venous thrombosis. 8:114B-127B. 1986
Diagnosis of pulmonary embolism. 8:128B-136B. 1986
EPIDEMIOLOGY AND PATHOGENESIS OF VENOUS THROMBOSIS. 8:B104-B113. 1986
Epidemiology and pathogenesis of venous thrombosis. 8:104B-113B. 1986
Dopamine: Its potential for inducing ischemic left ventricular dysfunction. 6:84-92. 1985
Coronary thrombosis and myocardial infarction. 2:785-785. 1983

Journal of the American College of Cardiology Journal

Overview

publication venue for

has subject area

Identity

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)